Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24258053 | 0.77 | ERCC1 (0.49) | ADORA2AKCNH2NPC1RAB9APNP | |
| SCHEMBL24258040 | 0.72 | KCNH2 (0.48) | KCNH2NPC1RAB9APNP | |
| SCHEMBL24258024 | 0.71 | KCNH2 (0.47) | KCNH2NPC1POLBRAB9APNP | |
| SCHEMBL26004959 | 0.69 | ADORA2A (0.54) | ADORA2AADORA1SCN3ANR1H2NR1H3 | |
| SCHEMBL5755658 | 0.69 | ADORA2A (0.44) | ADORA2AADORA1KCNH2RNASEH1PNP | |
| SCHEMBL31305393 | 0.69 | ADORA2A (0.44) | ADORA2AADORA1KCNH2RNASEH1PNP | |
| SCHEMBL13508771 | 0.68 | KCNH2 (1.00) | KCNH2POLB | |
| Hydrochloric Acid SCHEMBL6581517 | 0.68 | ADORA2A (0.60) | ADORA2AADORA1SCN3ANR1H2NR1H3 | |
| SCHEMBL22614959 | 0.66 | NR1I3 (0.63) | ADORA2AADORA1NR1H2 | |
| SCHEMBL13508758 | 0.66 | KCNH2 (0.86) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265082-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265082-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2022035805-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265082-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP1, USP18 | ADORA2A 4568/4885ADORA1 4198/4885KCNH2 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.